Rani Therapeutics Holdings (RANI) Amortizatization of Intangibles (2022 - 2026)
Rani Therapeutics Holdings (RANI) posted quarterly Amortizatization of Intangibles of $244000.0 for Q1 2026, up 62.67% year-over-year from $150000.0 in Q1 2025, and up 103.33% quarter-over-quarter from $120000.0 in Q4 2025.
Rani Therapeutics Holdings (RANI) Amortizatization of Intangibles (2022 - 2026) Analysis & Trends
Rani Therapeutics Holdings' Amortizatization of Intangibles history runs 5 years deep, the most recent figure standing at $244000.0 for Q1 2026.
- In Q1 2026, Amortizatization of Intangibles rose 62.67% year-over-year to $244000.0; the TTM figure through Mar 2026 stood at $372000.0 (down 64.81% YoY), while the FY2025 annual figure was $278000.0, down 77.71% from the prior year.
- Amortizatization of Intangibles for Q1 2026 stood at $244000.0, up from $120000.0 in the prior quarter.
- The five-year high for Amortizatization of Intangibles was $699000.0 in Q1 2023, with the low at $8000.0 in Q2 2025.
- The 5-year median for Amortizatization of Intangibles is $308500.0 (2024), against an average of $352571.4.
- The sharpest annual moves came in 2023 and 2025: Amortizatization of Intangibles jumped 190.0% in 2023, then slumped 97.24% in 2025.
- Rani Therapeutics Holdings' Amortizatization of Intangibles stood at $641000.0 in 2022, then slipped by 27.46% to $465000.0 in 2023, then tumbled by 33.98% to $307000.0 in 2024, then sank by 60.91% to $120000.0 in 2025, then surged by 103.33% to $244000.0 in 2026.
- Business Quant data shows RANI's Amortizatization of Intangibles at $244000.0 in Q1 2026, $120000.0 in Q4 2025, and $8000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Rani Therapeutics Holdings | 163.98 Mn | 163.98 Mn | - | 477,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 267,000.00 |
| Jun 30, 2026 | 267,000.00 |
| Mar 31, 2026 | 244,000.00 |
| Mar 31, 2026 | 244,000.00 |
| Dec 31, 2025 | 120,000.00 |
| Dec 31, 2025 | 120,000.00 |
| Jun 30, 2025 | 8,000.00 |
| Jun 30, 2025 | 8,000.00 |
| Mar 31, 2025 | 150,000.00 |
| Mar 31, 2025 | 150,000.00 |
| Dec 31, 2024 | 307,000.00 |
| Dec 31, 2024 | 307,000.00 |
| Sep 30, 2024 | 310,000.00 |
| Sep 30, 2024 | 310,000.00 |
| Jun 30, 2024 | 290,000.00 |
| Jun 30, 2024 | 290,000.00 |
| Mar 31, 2024 | 340,000.00 |
| Mar 31, 2024 | 340,000.00 |
| Dec 31, 2023 | 465,000.00 |
| Dec 31, 2023 | 465,000.00 |